Phase II, non-randomised, multicenter (GMMG-CONCEPT) Newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease Arm A: Isa-KRd followed by ASCT followed İsa-KRd (T

23 Sep

Follicular Lymphoma

New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma

Phase II, randomised (ROSEWOOD) Relapsed/refractory (R/R) follicular lymphoma (FL), who had ≥2 lines therapy Zanubritinib +Obinutuzumab (n=145) vs. Obinutuzumab (n=72)

23 Sep

Uterine Cancer

New Indication: Selinexor for Maintenance in Advanced Endometrial Cancer

Phase III, randomised, prospective, multicenter double-blind, placebo-controlled study (ENGOT-EN5/GOG-3055/SIENDO) Patients 18 years or older with histologically confirmed EC, who

23 Sep

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC

Multicenter, blinded, phase 2 study Previously treated (platinum-containing therapy) patients with HER2m mNSCLC Trastuzumab deruxtecan: 5.4 mg/kg (n=102) vs. 6.4 mg/kg (n=52)

23 Sep

Biliary Tract Cancer

New Reference: Erdafitinib for Advanced Solid Tumors with FGFR Alterations

Phase II, single-arm, multicohort (RAGNAR) Patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4

23 Sep

Soft Tissue Sarcoma

New Indication: Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Open-label, multicenter, phase 2 study Unresectable or metasatic ASPS Atezolizumab 1200 mg in adults (n=49) or 15 mg/kg (1200 mg max) in pediatric pts (n=3) once q21 days

20 Nov

GastroEsophageal Cancer

New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer

Double-blind, multicenter, randomised, phase 3 study (Keynote 859) Previously untreated locally advanced/metastatic HER2 negative GEJ and gastric adenocancer Pembrolizumab + Cht (n

23 Sep

Colorectal Cancer

New Protocol: Trifluridine-Tipiracil and Panitumumab for Refractory RAS WT Colorectal Cancer

Phase II, multicenter (VELO) Patients with refractory RAS WT mCRC Trifluridine-tipiracil +Panitimumab (n=31) vs. Trifluridine-tipiracil (n=31)

26 Nov

Hepatocellular Carcinoma

New Reference: Cabozantinib and Atezolizumab in HCC

Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries